cat no | io1117
ioGlutamatergic Neurons MAPT S305N;P301S/S305N;P301S
Human iPSC-derived neuronal 4R tau model
-
Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days
-
Functional excitatory neurons engineered with a double homozygous S305N and P301S mutation in MAPT for FTD, Alzheimer's disease and tauopathy research
-
Equimolar ratio of 4R:3R MAPT demonstrated by RT-qPCR and Western blotting
Place your order
Human iPSC-derived neuronal 4R tau model
ioGlutamatergic Neurons Media Kit
Cell culture media kit for the culture of ioGlutamatergic Neurons up to 14 days post-thaw
Adult-like 4R:3R tau isoform expression
MAPT isoform expression analysis by RT-qPCR, quantifying total, 3R and 4R MAPT expression in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells at days 11 and 32.
RNA (100 ng) was reverse-transcribed and amplified using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) and isoform-specific probes (total MAPT: Hs00902194_m1; 3R MAPT: Hs00902192_m1, 4R MAPT: Hs00902312_m1). Expression levels were normalised to HMBS and the 4R:3R MAPT ratio was calculated.
Western blot confirms the presence of 4R tau protein in MAPT S305N disease model cells
Total tau and 4R tau expression profiles in MAPT mutant ioGlutamatergic Neurons
Western blot analysis of total tau and 4R tau in wild-type (WT) vs. MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at days 11 and 32. The Western blot for total tau (A) shows the presence of the 4R and 3R isoforms in all MAPT mutant neurons whereas the WT control shows only 3R tau.
Cells were lysed in RIPA buffer with protease inhibitors; total protein was quantified via BCA Protein Assay kit. Lysates were pre-treated with lambda phosphatase (3h at 30°C).
Cell lysates and a tau ladder positive control were resolved on a 4–20% Mini-PROTEAN® TGX Stain-Free™ gel (120V, 90 min) and transferred to a PVDF membrane; 5 μg protein was loaded.
Membranes were blocked (10 min) and incubated overnight at 4°C with primary antibodies: Anti-Tau antibody [TAU-5] (abcam #ab80579, 1:1000), Tau 4R (E7T4F) Rabbit Monoclonal Antibody (Cell Signaling Technology #79327, 1:1000), or for the loading control, Anti-GAPDH antibody [6C5] (abcam #ab8245, 1:5000). Signal was detected via ECL following secondary antibody incubation.
MAPT S305N disease model cells show tau hyperphosphorylation
The S305N homozygous mutation drives tau hyperphosphorylation compared to the genetically matched wild-type control.
Western blot analysis of phospho-tau (p-tau) at days 11 and 32 in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells (A, B).
Cells were lysed in RIPA buffer with protease and phosphatase inhibitors; total protein was quantified via BCA Protein Assay Kit. Samples were resolved on a 4–20% Mini-PROTEAN® TGX Stain-Free™ gel (120V, 75 min) and transferred to a PVDF membrane; 10 μg protein was loaded.
Membranes were blocked (10 min) and incubated overnight at 4°C with primary antibodies: Phospho-Tau (Ser202, Thr205) Monoclonal Antibody (AT8) (Thermo Fisher #MN1020, 1:1000), Anti-Tau (phospho S396) antibody [E178] (abcam #ab32057, 1:1000), Anti-GAPDH antibody [6C5] (abcam #ab8245, 1:5000). Signal was detected via ECL following secondary antibody incubation.
Densitometry was performed relative to GAPDH signal using ImageJ and arbitrary units plotted (C, D).
4R tau is absent in the wild-type and most abundant in the MAPT S305N/S305N disease model cells
Representative immunocytochemistry images of 4R tau expression in wild-type (WT) and MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at day 32.
Cells were fixed in 4% PFA and stained for the neuronal marker Beta-III tubulin (TUBB3) and 4R tau (Cell Signaling Technology #79327). Fluorescent signals were visualised using an ImageXpress microscope.
Advanced tri-culture of ioGlutamatergic Neurons, ioAstrocytes 2.0, and ioMicroglia
While neuronal-astrocyte co-cultures capture essential structural and metabolic synergy, the addition of microglia, the resident myeloid cells of the CNS, is critical for accurately modelling neuroinflammatory pathways, synaptic pruning, and homeostatic maintenance.
This representative immunocytochemistry image demonstrates a successful tri-culture established at a 2:1:2 ratio (neurons:astrocytes:microglia). Using an optimised bit.bio protocol for 24-well plates, the tri-culture can be robustly maintained for up to 7 days. Staining with cell type-specific markers confirms the presence and integration of all three populations, shown alongside single-channel panels: MAP2-positive ioGlutamatergic Neurons (red), S100B-positive ioAstrocytes 2.0 (cyan), and IBA1-positive ioMicroglia (yellow); with DAPI as a nuclear counterstain (blue). Scale bars: 200 µm.
Efficient mRNA transfection into ioGlutamatergic Neurons
ioGlutamatergic Neurons are efficiently transfected and show sustained long-term expression of mRNA encoding GFP. ioGlutamatergic Neurons were imaged from day 1 post-thaw and throughout the experiment to assess transfection efficiency and evaluate potential cytotoxic effects of the transfection protocol. Day 1 images were captured prior to transfection on the same day.
Download the step-by-step protocol for lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons.
Lipid-based delivery of synthetic mRNA into ioGlutamatergic Neurons
ioGlutamatergic Neurons were transfected 24 hours post-thaw using Lipofectamine™ Stem Transfection Reagent. The transfection efficiency was evaluated by fluorescence imaging over 18 days after mRNA delivery, resulting in high transfection efficiency (close to 100%) and long-term sustained GFP expression.
Quantification of the GFP signal shows a decrease in GFP intensity over time, while the percentage of GFP-positive cells remains largely unchanged over time.
(A) The percentage of GFP-positive cells from two independent experiments.
(B) GFP intensity, quantified in successfully transfected cells from two independent experiments is quantified and normalised to day 2 (24 hours post-transfection).
Vial limit exceeded
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
A rapidly maturing, physiologically relevant, functional system for tauopathy, frontotemporal dementia (FTD) and Alzheimer's disease (AD) research.
ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] are opti‑ox deterministically programmed excitatory neurons engineered with a double homozygous S305N and P301S mutation in the MAPT gene.
While adult human brains express an equimolar ratio of 3R and 4R tau isoforms, traditional iPSC-derived neurons typically express very low levels of 4R tau, even in long-term culture. In this model, the homozygous S305N mutation accelerates exon 10 inclusion, driving an adult-like equimolar 4R:3R tau ratio by day 11 of culture, confirmed by RT-qPCR and Western blotting.
Additional disease model cells are available that carry the homozygous S305N mutation alone, or a homozygous S305N and heterozygous P301S mutation in the MAPT gene.
This model is genetically matched to our wild-type ioGlutamatergic Neurons, which serve as a robust control for translational research and high-throughput drug screening. It complements our broader Alzheimer's disease portfolio, which includes ioGlutamatergic Neurons carrying MAPT S305N, APP V717I, APP KM670/671NL, or PSEN1 M146L mutations, alongside disease-relevant mutations in ioGABAergic Neurons and ioMicroglia.
Benchtop benefits
Accelerated tauopathy model
Equimolar 4R:3R tau confirmed by RT-qPCR and Western blotting.
Make true comparisons
Pair with wild-type glutamatergic neurons to investigate the impact of the S305N and P301S double mutation.
Quick
Cells are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Cells arrive ready to plate

ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
Starting material
Human iPSC line
Karyotype
Normal (46, XY)
Seeding compatibility
6, 12, 24, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male, age 55-60 years old (skin fibroblast),
Genotype APOE 3/4
Vial size
Small: >1 x 10⁶ viable cells
Quality control
Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)
Differentiation method
opti-ox deterministic cell programming
Recommended seeding density
30,000 cells/cm²
User storage
LN2 or -150°C
Format
Cryopreserved cells
Genetic modification
Double homozygous S305N and P301S mutation in the MAPT gene
Applications
FTD, AD and tauopathy research
Drug discovery and development
Disease modelling
Product use
ioCells are for research use only
Scale your study with volume pricing
Enabling scientists to use human cells in their research, running additional experiments without rationing cells or limiting experimental scale
| Order quantity | Total vials received | Pricing tier |
| 1 - 9 packs | 3 - 27 vials | Standard price |
| 10 - 33 packs | 30 - 99 vials | Automatic 10% discount |
| > 34 packs | > 100 vials | > Contact us for a quote |
Adult-like 4R:3R tau isoform expression
Cells carrying the S305N mutation express equimolar 4R:3R MAPT isoforms by day 11
MAPT isoform expression analysis by RT-qPCR, quantifying total, 3R and 4R MAPT expression in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells at days 11 and 32.
RNA (100 ng) was reverse-transcribed and amplified using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) and isoform-specific probes (total MAPT: Hs00902194_m1; 3R MAPT: Hs00902192_m1, 4R MAPT: Hs00902312_m1). Expression levels were normalised to HMBS and the 4R:3R MAPT ratio was calculated.
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)
Western blot confirms the presence of 4R tau protein in MAPT S305N disease model cells
Total tau and 4R tau expression profiles in MAPT mutant ioGlutamatergic Neurons
Western blot analysis of total tau and 4R tau in wild-type (WT) vs. MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at days 11 and 32. The Western blot for total tau (A) shows the presence of the 4R and 3R isoforms in all MAPT mutant neurons whereas the WT control shows only 3R tau.
Cells were lysed in RIPA buffer with protease inhibitors; total protein was quantified via BCA Protein Assay Kit. Lysates were pre-treated with lambda phosphatase (3h at 30°C).
Cell lysates and a tau ladder positive control were resolved on a 4–20% Mini-PROTEAN® TGX Stain-Free™ gel (120V, 90 min) and transferred to a PVDF membrane; 5 μg protein was loaded.
Membranes were blocked (10 min) and incubated overnight at 4°C with primary antibodies: Anti-Tau antibody [TAU-5] (abcam #ab80579, 1:1000), Tau 4R (E7T4F) Rabbit Monoclonal Antibody (Cell Signaling Technology #79327, 1:1000), or for the loading control, Anti-GAPDH antibody [6C5] (abcam #ab8245, 1:5000). Signal was detected via ECL following secondary antibody incubation.
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)
The S305N homozygous mutation drives tau hyperphosphorylation compared to the genetically matched wild-type control.
Western blot analysis of phospho-tau (p-tau) at days 11 and 32 in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells (A, B).
Cells were lysed in RIPA buffer with protease and phosphatase inhibitors; total protein was quantified via BCA Protein Assay Kit. Samples were resolved on a 4–20% Mini-PROTEAN® TGX Stain-Free™ gel (120V, 75 min) and transferred to a PVDF membrane; 10 μg protein was loaded.
Membranes were blocked (10 min) and incubated overnight at 4°C with primary antibodies: Phospho-Tau (Ser202, Thr205) Monoclonal Antibody (AT8) (Thermo Fisher #MN1020, 1:1000), Anti-Tau (phospho S396) antibody [E178] (abcam #ab32057, 1:1000), Anti-GAPDH antibody [6C5] (abcam #ab8245, 1:5000). Signal was detected via ECL following secondary antibody incubation.
Densitometry was performed relative to GAPDH signal using ImageJ and arbitrary units plotted (C, D).
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)
4R tau is absent in the wild-type and most abundant in the MAPT S305N/S305N disease model cells
Representative immunocytochemistry images of 4R tau expression in wild-type (WT) and MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at day 32.
Cells were fixed in 4% PFA and stained for the neuronal marker Beta-III tubulin (TUBB3) and 4R tau (Cell Signaling Technology #79327). Fluorescent signals were visualised using an ImageXpress microscope.
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N hom (io1115)
ioGlutamatergic Neurons MAPT S305N hom P301S het (io1116)
Highly characterised and defined
ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] express neuron-specific markers comparably to the wild type control
Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] compared to the genetically matched control; (10x objective).
ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] form structural neuronal networks by day 11
ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; (10x objective).
ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic cell programming
Gene expression analysis demonstrates that ioGlutamatergic Neurons MAPT [S305N;P301S]/[S305N;P301S] and wild type ioGlutamatergic Neurons (WT Control) lack the expression of the pluripotency marker POU5F1 (OCT4) at day 11, while robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.
View the step-by-step RNA extraction and RT-qPCR protocol used to generate this data
Industry leading seeding density
The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
Adult-like 4R:3R tau isoform expression
MAPT isoform expression analysis by RT-qPCR, quantifying total, 3R and 4R MAPT expression in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells at days 11 and 32.
RNA (100 ng) was reverse-transcribed and amplified using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) and isoform-specific probes (total MAPT: Hs00902194_m1; 3R MAPT: Hs00902192_m1, 4R MAPT: Hs00902312_m1). Expression levels were normalised to HMBS and the 4R:3R MAPT ratio was calculated.
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)
Total tau and 4R tau expression profiles in MAPT mutant ioGlutamatergic Neurons
Western blot analysis of total tau and 4R tau in wild-type (WT) vs. MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at days 11 and 32. The Western blot for total tau (A) shows the presence of the 4R and 3R isoforms in all MAPT mutant neurons whereas the WT control shows only 3R tau.
Cells were lysed in RIPA buffer with protease inhibitors; total protein was quantified via BCA Protein Assay Kit. Lysates were pre-treated with lambda phosphatase (3h at 30°C).
Cell lysates and a tau ladder positive control were resolved on a 4–20% Mini-PROTEAN® TGX Stain-Free™ gel (120V, 90 min) and transferred to a PVDF membrane; 5 μg protein was loaded.
Membranes were blocked (10 min) and incubated overnight at 4°C with primary antibodies: Anti-Tau antibody [TAU-5] (abcam #ab80579, 1:1000), Tau 4R (E7T4F) Rabbit Monoclonal Antibody (Cell Signaling Technology #79327, 1:1000), or for the loading control, Anti-GAPDH antibody [6C5] (abcam #ab8245, 1:5000). Signal was detected via ECL following secondary antibody incubation.
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)
The S305N homozygous mutation drives tau hyperphosphorylation compared to the genetically matched wild-type control.
Western blot analysis of phospho-tau (p-tau) at days 11 and 32 in wild-type ioGlutamatergic Neurons (WT) and MAPT S305N disease model cells (A, B).
Cells were lysed in RIPA buffer with protease and phosphatase inhibitors; total protein was quantified via BCA Protein Assay Kit. Samples were resolved on a 4–20% Mini-PROTEAN® TGX Stain-Free™ gel (120V, 75 min) and transferred to a PVDF membrane; 10 μg protein was loaded.
Membranes were blocked (10 min) and incubated overnight at 4°C with primary antibodies: Phospho-Tau (Ser202, Thr205) Monoclonal Antibody (AT8) (Thermo Fisher #MN1020, 1:1000), Anti-Tau (phospho S396) antibody [E178] (abcam #ab32057, 1:1000), Anti-GAPDH antibody [6C5] (abcam #ab8245, 1:5000). Signal was detected via ECL following secondary antibody incubation.
Densitometry was performed relative to GAPDH signal using ImageJ and arbitrary units plotted (C, D).
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N/S305N (io1115)
ioGlutamatergic Neurons MAPT S305N/S305N+P301S/WT (io1116)
Representative immunocytochemistry images of 4R tau expression in wild-type (WT) and MAPT S305N/S305N (+P301S) ioGlutamatergic Neurons at day 32.
Cells were fixed in 4% PFA and stained for the neuronal marker Beta-III tubulin (TUBB3) and 4R tau (Cell Signaling Technology #79327). Fluorescent signals were visualised using an ImageXpress microscope.
View additional MAPT disease model product pages
ioGlutamatergic Neurons MAPT S305N hom (io1115)
ioGlutamatergic Neurons MAPT S305N hom P301S het (io1116)
Get started with
How to culture ioGlutamatergic Neurons
In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.
How to prepare tissue culture vessels with PDL-Geltrex for culture
Dr Kaiser Karim will take you through the step-by-step process of coating your culture plate with PDL-Geltrex before the revival of ioGlutamatergic Neurons.
Since recording this video Geltrex has been replaced by Geltrex Flex; refer to the user manual for full details.
Frequently Asked Questions (FAQs)
Why are the S305N and P301S mutations in the MAPT gene relevant for disease modelling?
The MAPT gene encodes tau, a microtubule-associated protein central to Alzheimer’s disease (AD) pathology. However, most pathogenic MAPT variants, including the S305N and P301S mutations, are associated with frontotemporal dementia (FTD). The S305N mutation, located in exon 10, destabilises a stem-loop structure, increasing both 4R tau expression and tau hyperphosphorylation.
The P301S mutation, also located in exon 10, similarly drives tau hyperphosphorylation. In patients, it enhances aggregation and seeding potency, and induces widespread transcriptomic and proteomic alterations. Consequently, ioGlutamatergic Neurons carrying a double homozygous S305N and P301S mutation in the MAPT gene serve as a human-relevant in vitro model for investigating the molecular and cellular mechanisms underlying FTD, AD and tauopathies.
What disease models are available from bit.bio to study the effects of mutations in the MAPT gene?
bit.bio offers ioGlutamatergic Neurons carrying a homozygous S305N MAPT mutation, either alone or paired with a heterozygous or homozygous P301S mutation. These three products enable scientists to study the synergistic impact of mutations in the MAPT gene alongside their genetically matched, wild-type control.
Is there a genetically matched wild-type control available for the MAPT S305N;P301S iPSC-derived neuronal model?
bit.bio offers the ioGlutamatergic Neurons carrying the double homozygous MAPT S305N and P301S mutation alongside a genetically matched wild-type control. Together, these ioGlutamatergic Neurons provide a physiologically relevant model to study how the S305N and P301S mutations drive FTD mechanisms and tau hyperphosphorylation in excitatory neurons.
Do the MAPT S305N;P301S ioGlutamatergic Neurons display phenotypic differences compared to the wild-type control?
The homozygous MAPT S305N mutation in ioGlutamatergic Neurons accelerates exon 10 inclusion, driving an adult-like, equimolar 4R:3R tau ratio by day 11 of culture, confirmed by RT-qPCR and Western blotting.
Documentation
Product resources
Cell culture hacks | human iPSC-derived glutamatergic neurons
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Wild Type and Isogenic Disease Model cells: A true comparison
Further your disease research by pairing our wild type cells with isogenic disease models.
ioCells catalogue
Human iPSC-derived cells
powered by opti-ox
Consistent. Defined. Scalable.